Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews · Eyes and Vision

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 25%High 1 · 25%

Summary of findings: bevacizumab vs ranibizumab

BCVA: gain of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration

Summary of findings: bevacizumab showed no clear difference in gain of 15 or more letters visual acuity at 1 year compared with ranibizumab (high certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 0.95 [0.81, 1.12]
8 studies · 3144 participants
High

Anti‐VEGF vs control

BCVA: gain of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment probably leads to higher gain of 15 or more letters visual acuity at 1 year compared with control (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 4.19 [2.32, 7.55]
6 studies · 2667 participants
Moderate

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid

Gain or loss of 10 or more letters visual acuity at 1 year · adults with centre‐involving diabetic macular oedema

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

Gain or loss of 10 or more letters visual acuity at 1 year · adults with centre‐involving diabetic macular oedema

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found